ProCE Banner Activity

TRITON3: Phase III Trial of Rucaparib vs Physician’s Choice Therapy in Metastatic CRPC With BRCA or ATM Alterations

Capsule Summary
Conference Coverage

Rucaparib reduced risk of radiographic progression or death by half vs physician’s choice therapy in patients with BRCA-altered mCRPC and progression following previous androgen receptor–directed therapy.

Released: February 21, 2023

Expiration: February 20, 2024

No longer available for credit.


Provided by

ProCE Banner


Supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.